Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Open-Label Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia and a CALR Mutation Previously Treated With Cytoreductive Therapy (EXCALIBUR-ET2)

NCT07623200 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT07623200
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07623200 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Open-Label Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia and a CALR Mutation Previously Treated With Cytoreductive Therapy (EXCALIBUR-ET2)
Lead sponsor
Incyte Corporation
Phase
Phase 3
Overall status
Recruiting
Start date
September 8, 2026
Completion date
November 1, 2030
Enrollment
426 (estimated)
Sites
178

Conditions

As the registry lists them; a condition with its own page is linked.

essential thrombocythemia